sb 202190 has been researched along with Bone Fractures in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Luo, D | 1 |
| Zhan, J | 1 |
| Hou, Y | 1 |
| Chen, S | 1 |
| Li, X | 1 |
| Lin, D | 1 |
1 other study available for sb 202190 and Bone Fractures
| Article | Year |
|---|---|
Fasudil enhanced differentiation of BMSCs in vivo and vitro, involvement of P38 signaling pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Biomarkers; Bone Marrow Cells; Cell Differen | 2020 |